AAV-focused gene therapy maker Capsida Biotherapeutics is laying off staff, the company confirmed to Fierce Biotech. The cuts could impact as much as 25% of the team, a source familiar with the decision said.
Gene therapy startup Capsida Biotherapeutics said it is laying off employees, months after unveiling two Big Pharma partnerships that brought in $125 million.
Capsida Biotherapeutics has appointed Susan Catalano Chief Scientific Officer (CSO).
Capsida Biotherapeutics is stepping beyond neurodegenerative conditions, diving into the world of eye disease with an AbbVie expansion pact for three gene medicine targets.
Prevail Therapeutics, the gene therapy-focused subsidiary of Eli Lilly, on Thursday announced a partnership with biotechnology company Capsida Biotherapeutics to develop genetic medicines for central nervous system diseases.
Capsida Biotherapeutics, a fully integrated biotechnology company creating a new class of targeted adeno-associated virus (AAV) gene therapies for patients with debilitating and life-threatening genetic disorders, has opened its state-of-the-art manufacturing facility in Thousand Oaks, CA.